Log in

NASDAQ:PHASPhaseBio Pharmaceuticals Stock Price, Forecast & News

+0.39 (+8.99 %)
(As of 07/14/2020 04:00 PM ET)
Today's Range
Now: $4.73
50-Day Range
MA: $4.93
52-Week Range
Now: $4.73
Volume285,107 shs
Average Volume555,047 shs
Market Capitalization$136.13 million
P/E RatioN/A
Dividend YieldN/A
PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapies to treat orphan diseases with an initial focus on cardiopulmonary indications. Its lead product candidate is PB2452, which is a reversal agent for the antiplatelet drug ticagrelor that has completed a Phase I clinical trial, as well as developing for the treatment of patients on ticagrelor who are experiencing a major bleeding event or those who require urgent surgery. The company is also developing PB1046, a fusion protein that is in Phase IIb clinical trial for the treatment of pulmonary arterial hypertension. The company has an agreement with Viamet Pharmaceuticals Holdings, LLC and Selenity Pharmaceuticals (Bermuda) Ltd. to develop PB6440, a lead development compound for treatment of resistant hypertension. PhaseBio Pharmaceuticals, Inc. was founded in 2002 and is based in Malvern, Pennsylvania.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.38 out of 5 stars

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:PHAS



Sales & Book Value

Annual Sales$2.36 million
Book Value$2.09 per share


Net Income$-39,250,000.00
Net Margins-2,310.60%


Market Cap$136.13 million
Next Earnings Date8/11/2020 (Estimated)
OptionableNot Optionable

Receive PHAS News and Ratings via Email

Sign-up to receive the latest news and ratings for PHAS and its competitors with MarketBeat's FREE daily newsletter.

PhaseBio Pharmaceuticals (NASDAQ:PHAS) Frequently Asked Questions

How has PhaseBio Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

PhaseBio Pharmaceuticals' stock was trading at $3.13 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, PHAS stock has increased by 51.1% and is now trading at $4.73. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of PhaseBio Pharmaceuticals?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for PhaseBio Pharmaceuticals in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for PhaseBio Pharmaceuticals.

When is PhaseBio Pharmaceuticals' next earnings date?

PhaseBio Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, August 11th 2020. View our earnings forecast for PhaseBio Pharmaceuticals.

How were PhaseBio Pharmaceuticals' earnings last quarter?

PhaseBio Pharmaceuticals Inc (NASDAQ:PHAS) posted its earnings results on Tuesday, May, 12th. The company reported ($0.52) EPS for the quarter, missing analysts' consensus estimates of ($0.42) by $0.10. The firm earned $0.32 million during the quarter, compared to the consensus estimate of $0.38 million. PhaseBio Pharmaceuticals had a negative net margin of 2,310.60% and a negative return on equity of 70.50%. View PhaseBio Pharmaceuticals' earnings history.

What price target have analysts set for PHAS?

6 brokerages have issued 12 month price targets for PhaseBio Pharmaceuticals' shares. Their forecasts range from $4.00 to $18.00. On average, they anticipate PhaseBio Pharmaceuticals' stock price to reach $13.00 in the next twelve months. This suggests a possible upside of 174.8% from the stock's current price. View analysts' price targets for PhaseBio Pharmaceuticals.

Has PhaseBio Pharmaceuticals been receiving favorable news coverage?

Media coverage about PHAS stock has trended positive recently, according to InfoTrie Sentiment. The research firm identifies positive and negative media coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. PhaseBio Pharmaceuticals earned a daily sentiment score of 2.2 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the company's share price in the immediate future. View the latest news about PhaseBio Pharmaceuticals.

Are investors shorting PhaseBio Pharmaceuticals?

PhaseBio Pharmaceuticals saw a increase in short interest in the month of June. As of June 30th, there was short interest totaling 2,250,000 shares, an increase of 13.6% from the June 15th total of 1,980,000 shares. Based on an average daily trading volume, of 696,200 shares, the days-to-cover ratio is currently 3.2 days. Approximately 15.2% of the shares of the company are short sold. View PhaseBio Pharmaceuticals' Current Options Chain.

Who are some of PhaseBio Pharmaceuticals' key competitors?

What other stocks do shareholders of PhaseBio Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other PhaseBio Pharmaceuticals investors own include Axsome Therapeutics (AXSM), SCYNEXIS (SCYX), Agile Therapeutics (AGRX), Amarin (AMRN), Viking Therapeutics (VKTX), VBI Vaccines (VBIV), TapImmune (MRKR), Selecta Biosciences (SELB), Zynerba Pharmaceuticals (ZYNE) and Dynavax Technologies (DVAX).

Who are PhaseBio Pharmaceuticals' key executives?

PhaseBio Pharmaceuticals' management team includes the following people:
  • Mr. Jonathan P. Mow, Pres, CEO & Director (Age 55, Pay $678.78k)
  • Mr. John P. Sharp, Chief Financial Officer (Age 55, Pay $548.51k)
  • Dr. John S. Lee, Chief Medical Officer (Age 52, Pay $581.5k)
  • Mr. Kristopher L. Hanson, VP, Head of Legal & Corp. Sec. (Age 48)
  • Mr. Michael B. York, VP of Corp. Devel. & Commercial Strategy (Age 55)

When did PhaseBio Pharmaceuticals IPO?

(PHAS) raised $66 million in an IPO on Thursday, October 18th 2018. The company issued 5,000,000 shares at a price of $12.50-$14.00 per share. Citigroup, Cowen and Stifel acted as the underwriters for the IPO and Needham was co-manager.

What is PhaseBio Pharmaceuticals' stock symbol?

PhaseBio Pharmaceuticals trades on the NASDAQ under the ticker symbol "PHAS."

How do I buy shares of PhaseBio Pharmaceuticals?

Shares of PHAS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is PhaseBio Pharmaceuticals' stock price today?

One share of PHAS stock can currently be purchased for approximately $4.73.

How big of a company is PhaseBio Pharmaceuticals?

PhaseBio Pharmaceuticals has a market capitalization of $136.13 million and generates $2.36 million in revenue each year. The company earns $-39,250,000.00 in net income (profit) each year or ($1.43) on an earnings per share basis. PhaseBio Pharmaceuticals employs 40 workers across the globe.

What is PhaseBio Pharmaceuticals' official website?

The official website for PhaseBio Pharmaceuticals is www.phasebio.com.

How can I contact PhaseBio Pharmaceuticals?

PhaseBio Pharmaceuticals' mailing address is 1 Great Valley Parkway Suite 30, Malvern PA, 19355. The company can be reached via phone at 610-981-6500 or via email at [email protected]

This page was last updated on 7/15/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.